January 5, 2007
Todd Hulgan of Vanderbilt University School of Medicine's Division of Infectious Diseases and colleagues conducted the study among 1,891 participants who began HAART regimens between 1997 and 2004 and received more than 30 days of therapy and who had baseline values of CD4+ T cell counts, CD4 percentages and HIV-1 RNA. The researchers used a proportional-hazard model to determine the link between CD4 percentage and disease progression and found that of the 1,891 participants, 468, or 25%, experienced disease progression during the study. They conducted a multivariable analysis that included age, race, sex, HIV-1 RNA, previous antiretroviral therapy, likely transmission route, prior AIDS-defining events, CD4 count and CD4 percentage. According to the study, previous antiretroviral therapy, injection drug use, and lower CD4 count and percentage predicted disease progression. The researchers concluded that CD4 percentage at the start of initial HAART regimens can predict disease progression independent of CD4 counts and that CD4 percentage can be used to determine the timing of HAART therapy (Hulgan et al., Journal of Infectious Diseases, February 2007).
Reprinted with permission from kaisernetwork.org. You can view the entire Kaiser Daily HIV/AIDS Report, search the archives, or sign up for email delivery at www.kaisernetwork.org/dailyreports/hiv. The Kaiser Daily HIV/AIDS Report is published for kaisernetwork.org, a free service of the Kaiser Family Foundation, by The Advisory Board Company. © 2006 by The Advisory Board Company and Kaiser Family Foundation. All rights reserved.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.